Acadia Healthcare Company, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Acadia Healthcare Company, Inc. on May 19, 2022. The report details the results of the Company's Annual Meeting of Stockholders held on the same date.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
The following matters were submitted to a vote of security holders:
- Election of Class II Directors: Three directors were elected to serve until the 2025 annual meeting.
- Jason R. Bernhard: Approved with 83,048,381 votes For, 1,425,379 Against, and 25,925 Abstain.
- William F. Grieco: Approved with 63,327,920 votes For, 21,145,829 Against, and 25,936 Abstain.
- Reeve B. Waud: Approved with 46,059,659 votes For, 38,243,796 Against, and 196,230 Abstain.
- Executive Compensation (Say-on-Pay): Stockholders approved the compensation of Named Executive Officers on a non-binding advisory basis with 83,326,381 votes For, 1,142,179 Against, and 31,125 Abstain.
- Ratification of Auditors: Stockholders ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2022, with 85,844,983 votes For, 599,745 Against, and 24,829 Abstain.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Verify the tenure of the newly elected Class II directors (Jason R. Bernhard, William F. Grieco, and Reeve B. Waud) through 2025.
- Note the significant "Against" votes for directors William F. Grieco (approx. 21.1M) and Reeve B. Waud (approx. 38.2M), indicating notable shareholder dissent despite their election.
- Confirm the ratification of Ernst & Young LLP as the auditor for the 2022 fiscal year.
- Review the definitive proxy statement filed on April 8, 2022, for details on the executive compensation package that received advisory approval.